Lintuzumab Ac-225/Venetoclax

N/A

Report date: 2023/11/15 16:18:30

Base Information

Drug NameLintuzumab Ac-225/Venetoclax
Drug Alias NameN/A
ClassificationRadiation-emitting products
Mechanisms of ActionIonising radiation emittersMyeloid cell surface antigen CD33 inhibitorsApoptosis regulator Bcl-2 inhibitors
TargetsMyeloid cell surface antigen CD33Apoptosis regulator Bcl-2
Therapy Area/IndicationsLeukemia, Promyelocytic, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Lintuzumab Ac-225Venetoclax
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesActinium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesActinium Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Promyelocytic, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A